Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer

20260 citationsJournal Articlegold Open Access

Authors

Paolo Tarantino · Harvard University

Jaeyoon Cha · Harvard University

Busem Binboga Kurt · Brigham and Women's Hospital

Xiangying Chu · Dana-Farber Cancer Institute

Bojana Jovanović · Harvard University

Xiao‐Hua Zhou · Harvard University

Melissa E. Hughes ·

Abstract

HER2-low expression is associated with hormone receptor (HR) expression in HR-positive breast cancer. We aimed to evaluate its association with androgen receptor (AR) among 196 patients with metastatic triple-negative breast cancer (mTNBC). Central determination of AR showed significant enrichment in HER2-low compared with HER2-0 mTNBC (mean: 33.7% vs. 21.4%, p = 0.038), whereas no significant immunological differences were observed. HER2-low/AR-positive patients trended towards longer overall survival, highlighting the potential relevance of these biomarkers.

Topics & Keywords

Breast Cancer Treatment Studies Advanced Breast Cancer Therapies Estrogen and related hormone effects

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: npj Breast Cancer

Volume 12, Issue 1

DOI: 10.1038/s41523-026-00913-4

Field-Weighted Citation Impact: 0.00